Investigational Drug Information for Navitoclax
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Navitoclax?
Navitoclax is an investigational drug.
There have been 27 clinical trials for Navitoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 29th 2020.
The most common disease conditions in clinical trials are Neoplasms, Leukemia, Lymphoid, and Leukemia. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.
There are five hundred and sixty-three US patents protecting this investigational drug and five international patents.
Summary for Navitoclax
| US Patents | 563 |
| International Patents | 5,578 |
| US Patent Applications | 1,845 |
| WIPO Patent Applications | 1,357 |
| Japanese Patent Applications | 609 |
| Clinical Trial Progress | Phase 2 (2020-09-29) |
| Vendors | 89 |
Recent Clinical Trials for Navitoclax
| Title | Sponsor | Phase |
|---|---|---|
| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | AbbVie | Phase 1 |
| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Jacqueline Garcia, MD | Phase 1 |
| Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | Thomas Jefferson University | Phase 1/Phase 2 |
Clinical Trial Summary for Navitoclax
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
US Patents for Navitoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Navitoclax | See Plans and Pricing | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | See Plans and Pricing |
| Navitoclax | See Plans and Pricing | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | See Plans and Pricing |
| Navitoclax | See Plans and Pricing | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| Navitoclax | See Plans and Pricing | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Navitoclax
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Navitoclax | Australia | AU2012322660 | 2031-10-11 | See Plans and Pricing |
| Navitoclax | Australia | AU2017228527 | 2031-10-11 | See Plans and Pricing |
| Navitoclax | Canada | CA2851788 | 2031-10-11 | See Plans and Pricing |
| Navitoclax | Canada | CA3173988 | 2031-10-11 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
